Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated August 8, 2025, reports a material update regarding the settlement of US mRNA patent litigation involving CureVac and BioNTech. The announcement details financial terms of the settlement and GSK's strategic position regarding its existing license agreement with CureVac.
Key Financial Metrics
- Upfront Settlement: GSK will receive a total settlement of $370 million.
- Cash Component: $320 million of the upfront settlement will be received in cash.
- Non-Cash Component: The remaining $50 million is attributed to the value of an amendment to GSK's existing agreement with CureVac, which includes significant royalty reductions for GSK's future mRNA products.
- Royalty Income: GSK will receive a 1% royalty on future US sales of influenza, COVID-19, and related combination mRNA vaccine products by BioNTech and Pfizer, effective from the beginning of 2025.
- Accounting Treatment: The $370 million upfront settlement will be recorded as other operating income as an adjusting item in the third quarter of 2025. Future royalty income will be recorded in total and core results.
Material Changes and Contingencies
The filing outlines a contingent scenario dependent on the pending acquisition of CureVac by BioNTech:
- Global Settlement: If the acquisition closes, the mRNA patent litigation outside the US will also be settled.
- Additional Cash: GSK would be entitled to an additional $130 million in cash.
- Global Royalties: GSK would receive 1% royalty payments on future sales outside the US by BioNTech and Pfizer.
- Cost Reductions: GSK would benefit from reduced milestones and lower royalties payable on its own sales of mRNA influenza and COVID-19 products outside the US.
Outlook, Risks, and Management Commentary
- Ongoing Litigation: This settlement does not impact GSK's enforcement of its own patents against Pfizer and BioNTech in the US and Europe. GSK will continue litigation against these entities for patent infringement.
- Share Tender: Simultaneously with the settlement, GSK entered into a tender and support agreement to tender approximately 16.6 million CureVac shares in the upcoming offer.
- Risk Factors: Forward-looking statements are subject to risks and uncertainties, including those described in GSK's 2024 Annual Report on Form 20-F and Q2 2025 Results.
Investor Verification Checklist
- Verify the closing status of the BioNTech acquisition of CureVac to confirm the potential $130 million additional cash payment and global royalty terms.
- Review the specific terms of the amendment to the GSK-CureVac agreement regarding royalty reductions for GSK's own products.
- Monitor the progress of GSK's separate patent infringement litigation against Pfizer and BioNTech.
- Confirm the timing of the $320 million cash receipt and its impact on Q3 2025 liquidity.